drugset
drugset / Trial / NCT05652660

A Study to Understand the Effect of a Study Medicine Called ARV-471 on Rosuvastatin in Healthy Adults

NCT05652660 ↗

Phase 1 Completed 12 enrolled Pfizer Arvinas Estrogen Receptor, Inc. · collab
NaCrossoverOpen-labelOther

Summary

The purpose of this study is to understand if ARV-471 affects how a BCRP substrate (rosuvastatin) gets into the body in healthy adults. All participants in this study will receive one dose of rosuvastatin alone by mouth in Period 1. In Period 2, everyone will receive one dose of ARV-471 by mouth 90 min before one dose of rosuvastatin by mouth. The levels of rosuvastatin in Period 1 will be compared to the levels of rosuvastatin in Period 2 to determine if ARV-471 affects how rosuvastatin gets into the body differently in healthy adults. All participants will stay at the study clinic for 10 days and 9 nights.

Timeline

Start
2022-12-09
Primary completion
2023-02-09
Completion
2023-03-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Rosuvastatin Small molecule — Oral
Subject vepdegestrant Other / unclassified — Oral

Indications

No indication recorded.